“Growing Demand for Minimally Invasive and Combination Procedures”
- A significant and accelerating trend in the global micro-invasive glaucoma implants market is the growing preference for minimally invasive surgical techniques, particularly those that can be performed alongside cataract surgery. This trend is enhancing patient outcomes while reducing recovery times and procedural risks
- For instance, iStent and Hydrus Microstent are commonly used in combination with phacoemulsification procedures, allowing ophthalmologists to address both cataract and glaucoma in a single surgical session. This dual-treatment approach improves surgical efficiency and appeals to both surgeons and patients
- Minimally invasive implants offer the advantage of preserving conjunctival tissue and reducing the need for postoperative interventions. Devices such as the XEN Gel Stent and OMNI Surgical System exemplify this innovation by offering effective intraocular pressure (IOP) control through micro-incisions and simplified implantation techniques
- The demand for such implants is rising among aging populations and glaucoma patients seeking alternatives to traditional filtration surgeries, which carry higher risks and longer recovery periods. As a result, healthcare providers and surgical centers are increasingly adopting MIGS as a first-line intervention for early-to-moderate glaucoma
- This trend is also supported by favorable reimbursement policies in several developed markets, such as the United States and parts of Europe, which are encouraging wider procedural adoption. In addition, training programs and increased surgeon familiarity with MIGS techniques are accelerating market penetration
- The preference for safer, faster, and less invasive glaucoma management solutions is reshaping the treatment landscape, prompting manufacturers to invest in newer device iterations and broadening the appeal of MIGS procedures across global ophthalmic markets
